We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the circumstances of a huge number of applied varieties and limited review resources, obtaining the right for priority review of enterprises’ pharmaceutical product applications can certainly largely reduce...
China's FDA published (Chinese) a slate of suggested amendments to its foreign drug registration rules Friday, which could dramatically revamp the country’s pharmaceutical market landscape by eliminating hurdles that slow approvals of Western drugs.
It gradually approaches the Chinese New Year holidays, but CFDA has never stopped its pace of intending to rectify the industry and continuing to introduce new policies.